Chase Investment Counsel’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.65M | Sell |
30,581
-5,299
| -15% | -$1.18M | 1.75% | 19 |
|
|
2025
Q4 | $8.2M | Buy |
35,880
+1,008
| +3% | +$230K | 2.29% | 11 |
|
|
2025
Q3 | $8.07M | Buy |
34,872
+29,990
| +614% | +$6.11M | 2.39% | 11 |
|
|
2025
Q2 | $906K | Hold |
4,882
| – | – | 0.29% | 69 |
|
|
2025
Q1 | $1.02M | Sell |
4,882
-18
| -0.4% | -$3.5K | 0.37% | 68 |
|
|
2024
Q4 | $870K | Sell |
4,900
-20
| -0.4% | -$3.68K | 0.28% | 78 |
|
|
2024
Q3 | $971K | Sell |
4,920
-22
| -0.4% | -$4.11K | 0.32% | 74 |
|
|
2024
Q2 | $847K | Buy |
4,942
+457
| +10% | +$75.7K | 0.3% | 78 |
|
|
2024
Q1 | $816K | Buy |
4,485
+181
| +4% | +$31.2K | 0.3% | 78 |
|
|
2023
Q4 | $666K | Hold |
4,304
| – | – | 0.29% | 81 |
|
|
2023
Q3 | $641K | Buy |
4,304
+66
| +2% | +$9.69K | 0.32% | 74 |
|
|
2023
Q2 | $570K | Sell |
4,238
-1,940
| -31% | -$284K | 0.29% | 63 |
|
|
2023
Q1 | $984K | Sell |
6,178
-24,912
| -80% | -$3.81M | 0.54% | 54 |
|
|
2022
Q4 | $5.02M | Sell |
31,090
-16,177
| -34% | -$2.48M | 3.07% | 3 |
|
|
2022
Q3 | $6.34M | Sell |
47,267
-447
| -0.9% | -$64.1K | 4.01% | 3 |
|
|
2022
Q2 | $7.31M | Sell |
47,714
-2,960
| -6% | -$452K | 3.94% | 3 |
|
|
2022
Q1 | $8.21M | Buy |
50,674
+1,747
| +4% | +$254K | 3.59% | 5 |
|
|
2021
Q4 | $6.62M | Buy |
48,927
+26,347
| +117% | +$3.11M | 2.65% | 7 |
|
|
2021
Q3 | $2.44M | Buy |
22,580
+279
| +1% | +$31.9K | 1.05% | 38 |
|
|
2021
Q2 | $2.51M | Hold |
22,301
| – | – | 1.04% | 39 |
|
|
2021
Q1 | $2.41M | Buy |
22,301
+475
| +2% | +$50.8K | 1.1% | 39 |
|
|
2020
Q4 | $2.34M | Hold |
21,826
| – | – | 1.03% | 41 |
|
|
2020
Q3 | $1.91M | Buy |
21,826
+95
| +0.4% | +$8.94K | 0.95% | 44 |
|
|
2020
Q2 | $2.13M | Buy |
21,731
+18,016
| +485% | +$1.59M | 1.08% | 38 |
|
|
2020
Q1 | $283K | Sell |
3,715
-12,805
| -78% | -$1.09M | 0.19% | 52 |
|
|
2019
Q4 | $1.46M | Buy |
+16,520
| New | +$1.37M | 0.74% | 44 |
|
|
2019
Q1 | – | Sell |
-2,809
| Closed | -$258K | – | 97 |
|
|
2018
Q4 | $258K | Sell |
2,809
-90
| -3% | -$7.92K | 0.15% | 76 |
|
|
2018
Q3 | $274K | Buy |
2,899
+602
| +26% | +$57.1K | 0.14% | 82 |
|
|
2018
Q2 | $212K | Buy |
2,297
+75
| +3% | +$7.33K | 0.11% | 83 |
|
|
2018
Q1 | $210K | Buy |
2,222
+100
| +5% | +$11K | 0.11% | 81 |
|
|
2017
Q4 | $205K | Sell |
2,122
-188
| -8% | -$17.7K | 0.11% | 76 |
|
|
2017
Q3 | $205K | Buy |
+2,310
| New | +$176K | 0.11% | 80 |
|
|
2016
Q4 | – | Sell |
-53,209
| Closed | -$3.35M | – | 90 |
|
|
2016
Q3 | $3.35M | Sell |
53,209
-10,635
| -17% | -$688K | 1.48% | 33 |
|
|
2016
Q2 | $3.95M | Buy |
63,844
+239
| +0.4% | +$14.6K | 1.75% | 27 |
|
|
2016
Q1 | $3.63M | Buy |
63,605
+680
| +1% | +$37.9K | 1.59% | 30 |
|
|
2015
Q4 | $3.73M | Sell |
62,925
-5,240
| -8% | -$302K | 1.48% | 35 |
|
|
2015
Q3 | $3.71M | Buy |
68,165
+5,078
| +8% | +$331K | 1.5% | 34 |
|
|
2015
Q2 | $4.24M | Sell |
63,087
-2,017
| -3% | -$132K | 1.54% | 33 |
|
|
2015
Q1 | $3.81M | Sell |
65,104
-12,434
| -16% | -$751K | 1.34% | 32 |
|
|
2014
Q4 | $5.07M | Sell |
77,538
-3,934
| -5% | -$248K | 1.81% | 25 |
|
|
2014
Q3 | $4.71M | Sell |
81,472
-8,647
| -10% | -$480K | 1.69% | 24 |
|
|
2014
Q2 | $5.09M | Sell |
90,119
-4,572
| -5% | -$240K | 1.72% | 24 |
|
|
2014
Q1 | $4.87M | Sell |
94,691
-20,419
| -18% | -$1.03M | 1.65% | 29 |
|
|
2013
Q4 | $6.08M | Sell |
115,110
-47,620
| -29% | -$2.34M | 1.8% | 24 |
|
|
2013
Q3 | $7.28M | Sell |
162,730
-3,400
| -2% | -$151K | 1.87% | 31 |
|
|
2013
Q2 | $6.87M | Buy |
+166,130
| New | +$7.27M | 1.83% | 28 |
|
Other funds holding ABBV
VCM
VPM
Chase Investment Counsel's ABBV Position: Q1 2026 in Review
Chase Investment Counsel reduced its AbbVie (ABBV) stake by 15% in Q1 2026, selling an estimated $1.18M and leaving 30,581 shares worth $6.65M. The position accounts for 1.75% of the portfolio, ranked #19.
Chase Investment Counsel first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. The position peaked at $8.21M in Q1 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Chase Investment Counsel held 30,581 shares of AbbVie worth $6.65M as of Q1 2026.
- Chase Investment Counsel sold 5,299 AbbVie shares in Q1 2026, an estimated $1.18M.
- AbbVie made up 1.75% of Chase Investment Counsel's portfolio in Q1 2026, its #19 holding.
- Chase Investment Counsel first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
- Chase Investment Counsel's AbbVie position peaked at $8.21M in Q1 2022.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Chase Investment Counsel's 13F filing for Q1 2026, filed 12 May 2026.